Tilray | TRLY - Ebit


Tilray reported $-20.01M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acasti Pharma USD -3.7M 1.13M Dec/2024
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Aurora Cannabis CAD 7.12M 42.91M Mar/2026
Avita Medical AUD -10.39M 1.72M Dec/2025
Canopy Growth CAD -145.65M 132.99M Mar/2026
Cronos Group USD -1.45M 5.61M Mar/2026
Dianthus Therapeutics USD -46.53M 23.01M Mar/2026
Divis Laboratories Ltd INR 11.29B 3.15B Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
IQVIA Holdings USD 2.6B 2.03B Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Moderna USD -815M 573M Jun/2026
Organigram Holdings CAD -9.79M 10.33M Mar/2026
Organon & Co USD 324M 351M Mar/2026
Revvity USD 126.14M 43.36M Jun/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD -20.2M 137.3M Mar/2026
Xeris Pharmaceuticals USD 9.12M 7.65M Mar/2026
Zealand Pharma A/S -389M 318.05M Mar/2026